Search Results - patrick+ross

3 Results

Sort By:

Unmet NeedDrug resistance to antibiotics, especially β-lactam antibiotics such as penicillin, cephalosporin and related compounds is one of the most serious problems in the treatment of infectious diseases. It represents not only a significant medical problem, but a major public health and economic burden. Reports from the Center for Disease Control...

Published: 5/9/2024 | Inventor(s): Samuel Milstein, Irene Luque, Xiao Yingxin, Raphael Ottenbrite, Patrick Ross, Ernesto Freire

Keywords(s): Antagonists/Inhibitors, Bacterial Infections, Disease Indication, Infectious Diseases, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections

High Affinity Beta Lactamase Inhibitors

C11674: Novel Beta-Lactamase InhibitorsNovelty: This technology comprises of a series of compounds based on a novel scaffold that selectively inhibits the enzyme, beta lactamase with high affinity thereby providing a potential solution to beta-lactam resistance in bacteria.Value Proposition: Development of resistance to currently available beta-lactam...

Published: 5/9/2024 | Inventor(s): Ernesto Freire, Rogelio Siles, Patrick Ross

Keywords(s): Antagonists/Inhibitors, Antibiotic, Bacterial Infections, Disease Indication, Infectious Diseases, Novel, Predicted Novelty, Single, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules

High Affinity Chymase Inhibitors

C11636: Novel Chymase Inhibitors for Treatment of AtherosclerosisNovelty: This technology comprises of a series of compounds based on a novel scaffold allowing for selective inhibition of chymase, an enzyme implicated in the development of atheroscleriosis.Value Proposition: Activation of the enzyme chymase, a serine protease sets off a cascade of events...

Published: 5/9/2024 | Inventor(s): Rogelio Siles, Patrick Ross, Ernesto Freire

Keywords(s): Antagonists/Inhibitors, Biomarker, Cardiovascular Diseases, Disease Indication, Mechanism-of-action Biomarker, Novel, Predicted Novelty, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Atherosclerosis